On April 4, 2022 HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, reported that three posters featuring two pipeline programs (HFB200603 and HFB101110) and our Drug Intelligent Science (DIS) driven predictive biomarker approach will be presented at AACR (Free AACR Whitepaper) 2022, which will be held April 8-13, 2022, in New Orleans, LA (Press release, HiFiBiO Therapeutics, APR 4, 2022, View Source [SID1234611402]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to share with the oncology research community at AACR (Free AACR Whitepaper) updates for two of our preclinical development programs – HFB200603, a novel anti-BTLA blocking antibody on track for IND submission, and HFB101110, an anti-CCR8 depleting antibody that was recently licensed to FibroGen. We will also present work using our DISTM approach to discover predictive biomarkers of response for our clinical programs HFB200301, a first in class TNFR2 agonist and HFB301001, a differentiated second generation OX40 agonist for the treatment of advanced DISTM selected solid tumors," said Francisco Adrian, Chief Scientific Officer of HiFiBiO Therapeutics. "HiFiBiO’s innovative DIS approach leveraging single cell capabilities is positioned to transform the drug discovery and development paradigm by integrating deep understanding of immune-modulation with a world-leading single cell platform and machine learning-enabled data analysis."
Details on the posters are as follows:
Title: HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
Permanent Abstract Number: 4248
Session: Therapeutic Antibodies 3
Session Date and Time: Wednesday, April 13, 2022; 9:00 am – 12:30 pm
Venue: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 39
Title: Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Permanent Abstract Number: 2899
Session: Therapeutic Antibodies 2
Session Date and Time: Tuesday, April 12, 2022; 9:00 am – 12:30 pm
Venue: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38
Title: Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Permanent Abstract Number: 618
Session: Immune Response to Therapies 2 / Immune Monitoring and Clinical Correlates
Session Date and Time: Sunday, April 10, 2022, 1:30 – 5pm
Venue: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 39